Ingrid Nijholt

Dr. Ingrid Nijholt

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in European Journal of Radiology
Verified
Journal Article
Closed access
KAKimberley J. Anneveldt
Kimberley J. Anneveldt
HOHeleen J. van ’t Oever
Heleen J. van ’t Oever
INIngrid Nijholt
Ingrid Nijholt
JDJeroen R. Dijkstra
Jeroen R. Dijkstra
WHWouter J. Hehenkamp
Wouter J. Hehenkamp
MBMartijn F. Boomsma
Martijn F. Boomsma

24 November 2021 in JMIR Research Protocols
Verified
Journal Article
Open access
KAKimberley J Anneveldt
Kimberley J Anneveldt
INIngrid Nijholt
Ingrid Nijholt
JSJoke M Schutte
Joke M Schutte
JDJeroen R Dijkstra
Jeroen R Dijkstra
GFGeert W J Frederix
Geert W J Frederix
MBMartijn Boomsma
Martijn Boomsma
Background: Magnetic resonance image–guided high-intensity–focused ultrasound (MR-HIFU) is a rather new, noninvasive option for the treatment of uterine fibroids. It is safe, effective, and has a very short recovery time. However, a lack of prospectively collected data on long-term (cost-)effectiveness of the MR-HIFU treatment compared with standard uterine fibroid care prevents the MR-HIFU treatment from being reimbursed for this indication. Therefore, at this point, when conservative treatment for uterine fibroid symptoms has failed or is not accepted by patients, standard care includes the more invasive treatments hysterectomy, myomectomy, and uterine artery embolization (UAE). Primary outcomes of currently available data on MR-HIFU treatment often consist of technical outcomes, instead of patient-centered outcomes such as quality of life (QoL), and do not include the use of the latest equipment or most up-to-date treatment strategies. Moreover, data on cost-effectiveness are rare and seldom include data on a societal level such as productivity loss or use of painkillers. Because of the lack of reimbursement, broad clinical implementation has not taken place, nor is the proper role of MR-HIFU in uterine fibroid care sufficiently clear. Objective: The objective of our study is to determine the long-term (cost-)effectiveness of MR-HIFU compared with standard (minimally) invasive fibroid treatments. Methods: The MYCHOICE study is a national, multicenter, open randomized controlled trial with randomization in a 2:1 ratio to MR-HIFU or standard care including hysterectomy, myomectomy, and UAE. The sample size is 240 patients in total. Women are included when they are 18 years or older, in premenopausal stage, diagnosed with symptomatic uterine fibroids, conservative treatment has failed or is not accepted, and eligible for MR-HIFU. Primary outcomes of the study are QoL 24 months after treatment and costs of treatment including direct health care costs, loss of productivity, and patient costs. Results: Inclusion for the MYCHOICE study started in November 2020 and enrollment will continue until 2024. Data collection is expected to be completed in 2026. Conclusions: By collecting data on the long-term (cost-)effectiveness of the MR-HIFU treatment in comparison to current standard fibroid care, we provide currently unavailable evidence about the proper place of MR-HIFU in the fibroid treatment spectrum. This will also facilitate reimbursement and inclusion of MR-HIFU in (inter)national uterine fibroid care guidelines. Trial Registration: Netherlands Trial Register NL8863; https://www.trialregister.nl/trial/8863 International Registered Report Identifier (IRRID): DERR1-10.2196/29467

8 August 2025 in Thrombosis Research
Verified
Journal Article
Open access
WSW.J.E. Stenger
W.J.E. Stenger
CUCorstiaan Den Uil
Corstiaan Den Uil
WRW.J.R. Rietdijk
W.J.R. Rietdijk
IAI. Al Amri
I. Al Amri
JMJose Montero-Cabezas
Jose Montero-Cabezas
JJJ. Jongkind
J. Jongkind
Catheter-directed thrombectomy (CDT) is a promising alternative to full dose thrombolysis in patients with acute high-risk pulmonary embolism (PE), expected to have a more direct effect on pulmonary artery clot burden and a better safety profile. Randomized trials evaluating the safety and efficacy of CDT in high-risk patients are currently unavailable. The TORPEDO-NL study is an investigator-initiated, publicly-funded, multicenter, open-label randomized controlled trial designed to evaluate the superiority of CDT over systemic thrombolysis in patients with high-risk PE. Adults with: 1) confirmed acute PE, 2) a high risk for mortality, and 3) CDT available and technically feasible, will be randomized 2:1 to CDT versus systemic thrombolysis. The primary outcome is the composite incidence of all-cause mortality, treatment failure, major bleeding, and all-cause stroke at day 30. Secondary outcomes include desirability of outcome ranking (DOOR) at day 7, length of hospital stay, patient-reported outcomes including quality of life and symptom burden, functional recovery, and 1-year cost-effectiveness. The trial anticipates recruiting 111 patients and is funded by the The Netherlands Health Care Institute, The Netherlands Organization for Health Research and Development, the Dutch Heart Foundation, and unrestricted grants from Penumbra Inc. and Inari Medical. gov number, NCT06833827. TORPEDO-NL is the first publicly-funded randomized trial to investigate the effect of CDT treatment specifically in high-risk PE patients. The trial is anticipated to play an important role in revising recommendations for high-risk PE treatment in international guidelines.

17 January 2022 in European Journal of Radiology
Verified
Journal Article
Closed access
M. SellesM. Selles
M. Selles
JKJ.H. Korte
J.H. Korte
HBH.J. Boelhouwers
H.J. Boelhouwers
INIngrid Nijholt
Ingrid Nijholt
JOJ.A.C. van Osch
J.A.C. van Osch
MBMartijn Boomsma
Martijn Boomsma

1 November 2021 in Radiology
Verified
Journal Article
Closed access
ELEline Langius-Wiffen
Eline Langius-Wiffen
INIngrid Nijholt
Ingrid Nijholt
EBErwin de Boer
Erwin de Boer
JNJacqueline Nijboer-Oosterveld
Jacqueline Nijboer-Oosterveld
LHLisa Huurman
Lisa Huurman
MBMartijn Boomsma
Martijn Boomsma
Download as PowerPoint

28 January 2024 in Journal of Ultrasound
Verified
Journal Article
Closed access
PDF file
SBSietske Bergsma
Sietske Bergsma
MGMargo van Gent
Margo van Gent
ADAlida J. Dam-Vervloet
Alida J. Dam-Vervloet
MLMartine C. M. Lagerweij
Martine C. M. Lagerweij
EWEgbert-Jan van der Wouden
Egbert-Jan van der Wouden
LPLieke Poot
Lieke Poot